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The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and
demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant
5-fluorouracil (5FU)/leucovorin therapy. One hundred and thirty consecutive, B2 and C Duke’s stage colorectal cancer patients were
prospectively enrolled. 5FU pharmacokinetics was evaluated at the first cycle. Thymidylate synthase (TYMS)5 0UTR and 30UTR
polymorphisms and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms were assessed in peripheral
leukocytes. Univariate and multivariate analyses were applied to evaluate which variables could predict chemotherapy-induced
toxicity, disease-free survival (DFS) and overall survival (OS). Multivariate analysis showed that: (a) low 5FU clearance was an
independent predictive factor for severe toxicity (OR¼7.32; Po0.0001); (b) high-5FU clearance predicted poorer DFS (HR¼1.96;
P¼0.041) and OS (HR¼3.37; P¼0.011); (c) advanced age was associated with shorter DFS (HR¼3.34; P¼0.0008) and OS
(HR¼2.66; P¼0.024); (d) the C/C genotype of the MTHFR C677T polymorphism was protective against grade 3–4 toxicity
(P¼0.040); (e) none of the TYMS polymorphisms could explain 5FU toxicity or clinical outcome.
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Fluorouracil (5FU) is a fundamental component of all chemothera-
pic combinations for palliative (Board and Valle, 2007) and
adjuvant treatments (Chung and Saltz, 2007) of colorectal cancer.
Its main mechanism of action consists of inhibition of thymidylate
synthase (TS) through an active metabolite, fluorodeoxyuridine
monophosphate (FdUMP), which forms an inactive ternary
complex with TS and 5–10 methylenetetrahydrofolate (MTHF)
(Pinedo and Peters, 1988). Intracellular MTHF levels, which are
essential for ternary complex stabilisation, are controlled by the
enzyme methylenetetrahydrofolate reductase (MTHFR) (Scott and
Weir, 1994). Consequently, the tissue activities of TS and MTHFR
are presumed to be major determinants of 5FU clinical response.
The activity of both enzymes is under genetic control and several
gene polymorphisms are known to influence their tissue expres-
sion. A variable number of 28bp tandem repeats (VNTR) is
present in the 50-untranslated region (50-UTR) of the TS gene
(TYMS). The allele containing the triple repeat (3R) is associated
with 3–4-fold translational efficiency, compared with the double
repeat allele (2R) (Kawakami et al, 2001). A second polymorphism
has been identified in the second 28bp repeat of 3R alleles,
consisting of a G4C base change at the twelfth nucleotide, which
makes the transcriptional activity of the 3R allele as low as that of
the 2R allele (Mandola et al, 2003). Third, a 6bp deletion may
occur in the 30-untranslated region (30-UTR) of TYMS, associated
with decreased mRNA stability and lower TS expression (Mandola
et al, 2004). Two functionally important single nucleotide
polymorphisms (SNP) have also been detected in the MTHFR
gene (MTHFR), C677T and A1298C, resulting in decreased MTHFR
activity (Ulrich et al, 2002).
Despite these theoretical and experimental premises, clinical
studies which have evaluated the effect of TYMS (Gusella and
Padrini, 2007) and MTHFR (Robien et al, 2005) polymorphisms on
the colorectal cancer response/toxicity to 5FU have produced
inconsistent results.
An additional determinant of 5FU activity is the metabolic rate
of dihydropyrimidine dehydrogenase (DPD), the enzyme respon-
sible for 5FU inactivation (van Kuilenburg, 2004). Variability in
DPD activity is only marginally explained by genetic factors, as
deficient variants of DPD gene are extremely rare (van Kuilenburg
et al, 2001). Hence, DPD activity is best determined by direct
in vivo measurement of 5FU plasma clearance (CL).
The aim of our work was to evaluate the clinical outcome and
toxicity of colorectal cancer patients on adjuvant treatment with
5FU in relation with demographic characteristics, known TYMS
and MTHFR polymorphisms, and individual 5FU CL.
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sMATERIALS AND METHODS
Patients and treatment
A total of 130 consecutive B2 and C Duke’s stage colorectal cancer
patients on adjuvant therapy were prospectively studied between
1999 and 2008. Chemotherapeutic treatment consisted of
the 5FUþleucovorin combination according to the Mayo admin-
istration schedule (O’Connel et al, 1997) (2min i.v. bolus
administration of 425mgm
–2 5FUþ20mgm
–2 folinic acid daily
for 5 days, for 6 consecutive cycles every 4 weeks). The starting
dose could be reduced by 25% in the oldest patients. If toxicity of
grade X2 occurred, the next doses were reduced by 25–50% or
stopped, according to toxicity level. The study was approved by the
Ethics Committee of the Azienda–ULSS 18 Rovigo, and all patients
gave their written informed consent.
Clinical evaluation
Toxicity was recorded and graded according to World Health
Organization (WHO) criteria and was dichotomously classified for
statistical analysis in none-to-moderate (grade 0–2) and severe
(grade 3–4).
The outcome variables were disease-free survival (DFS) and
overall survival (OS). For DFS, an event was defined as the first
occurrence of a tumour relapse that was not preceded by a second
primary cancer. For OS, the outcome was death related to cancer
and patients who died for other causes were treated as censored in
survival analysis. The duration of follow-up was measured from
the date of starting chemotherapy. Follow-up visits were scheduled
every 3 months in the first year, every 6 months in the second and
third years, and every year thereafter.
Pharmacokinetic analysis
5FU pharmacokinetics was determined on day 2 of the first
therapy cycle, using an HPLC method and a limited sampling
strategy described earlier (Gusella et al, 2002). Plasma concentra-
tion decay was analysed with a mono-exponential function, so that
intercept (A) and slope (k) were obtained and used to calculate the
main pharmacokinetic parameters:
  area under the plasma concentration-time curve: AUC¼A/k;
  plasma clearance: CL¼Dose/AUC.
With the limited sampling methods used, bias and accuracy for
AUC estimate are 3.4 and 5.1%, respectively (Gusella et al, 2002).
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes
with a commercial kit (Promega Corporation, Madison, WI, USA)
and stored at 41C until genotyping. 0.2mg per sample of genomic
DNA was used to carry out the PCR using specific primers in a
50ml final volume; genotyping was carried out according to earlier
reported methods for TYMS 50UTR VNTR and G4C substitution
(Gusella et al, 2006a), TYMS 30UTR 6bp insert-deletion (Ulrich
et al, 2000), MTHFR C677T and MTHFR A1298C polymorphisms
(Miao et al, 2002).
Repeat genotyping of a 10% random sample yielded a 100%
agreement.
Classification of TS expression based on combined 50UTR
and 30UTR genotypes
Variable number of tandem repeats and G4C SNP polymorphisms
in the 50UTR were classified according to Kawakami and Watanabe
(2003) in low expression (2R/2R, 2R/3RC, 3RC/3RC) and high-
expression TS genotypes (2R/3RG, 3RC/3RG, 3RG/3RG). 50UTR
and 30UTR were also combined in two different ways, based on the
expected TS expression level (see Table 1). The simplest
combination (combination A) takes into account VNTR and
ins/del 30UTR polymorphisms and classifies TS activity as ‘high’ or
‘low’, according to Hitre et al (2005). The more complex
combination (combination B) also includes G4C SNP in the
50UTR and divides TS activity into three expression groups: ‘high’,
‘intermediate’ and ‘low’.
Classification of MTHFR activity based on combined
C677T and A1298C genotypes
Similarly, MTHFR activity was classified as ‘high’, ‘intermediate’
and ‘low’, based on the expected MTHFR metabolic rate of the
combined C677T and A1298C polymorphisms (Ulrich et al, 2002)
(see Table 2).
Statistical analysis
Univariate logistic regression was used to identify the baseline
prognostic factors related to toxicity. The factors significant at the
0.20 level were then introduced in a multivariate logistic regression
Table 1 TYMS combined genotypes classified according to expected expression of thymidylate synthase
Expression level TYMS 50UTR TYMS 30UTR n
G4C SNP (Kawakami and Watanabe, 2003) High 2R/3RG,3RC/3RG, 3RG/3RG — 58
Low 2R/2R, 2R/3RC, 3RC/3RC — 72
Combination A (Hitre et al, 2005) High 3R3R Any genotype 61
2R3R ins/ins
Low 2R3R ins/del–del/del 69
2R2R any genotype
High 2R/3RG,3RC/3RG, 3RG/3RG ins/ins 8
Combination B Intermediate 2R/3RG,3RC/3RG, 3RG/3RG ins/del–del/del 88
2R/2R, 2R/3RC, 3RC/3RC ins/ins
Low 2R/2R, 2R/3RC, 3RC/3RC ins/del–del/del 34
Abbreviations: SNP¼single nucleotide polymorphism; UTR¼untranslated region.
Table 2 MTHFR combined genotypes classified according to expected
activity of metylenetetrahydrofolate reductase
Activity level MTHFR C677T MTHFR A1298C N
High C/C A/A 10
Intermediate C/C C/C, A/C 78
T/T, C/T A/A
Low T/T, C/T C/C, A/C 42
Abbreviation: MTHFR¼methylenetetrahydrofolate reductase.
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Interactions were tested at the 0.10 level of significance. The
results are presented as odds ratio (OR) and 95% confidence
interval.
The hazard ratios (HRs) for disease recurrence and mortality,
were estimated for individual covariates with the univariate Cox
proportional-hazards model. Variables significant at the 0.20 level
in the univariate analysis were entered into multivariate Cox
proportional-hazards models in a backward selection procedure.
Interactions were tested at the 0.10 level of significance.
Proportionality assumption was tested including time-dependent
covariates in the final model at a significance level of 0.10. The
results are presented as HR and 95% confidence interval.
Covariates considered were age (two groups divided by the
median value), sex, Dukes’ stage (B2 and C), TYMS VNTR
polymorphism (three genotypes), TYMS G4C SNP polymorphism
(low- and high-expression genotypes), TYMS ins/del poly-
morphism (three genotypes), TYMS 50UTR and 30UTR combined
genotypes (combination A: two groups; combination B: three
groups; see Table 1), MTHFR C677T polymorphism (three
genotypes), MTHFR A1298C polymorphism (three genotypes),
MTHFR 677 and 1298 combined genotypes (three groups; see
Table 2), 5FU clearance per Kg (two groups divided by median
value) and true cumulative 5FU dose administered, expressed as a
percentage of the theoretical dose (continuous).
Survival curves were estimated using the Kaplan–Meier method
and differences between individual curves were assessed by log-
rank test. Data are presented as means±s.d., unless otherwise
specified. The w
2-test and t-test for unpaired data were applied to
compare frequencies and means, respectively. A one-way ANOVA
(followed by the post-hoc linear-trend test, when needed) was used
to compare groups. All tests were two-sided with a 5% significance
level. Data were analysed with version 9.1.3 of SAS software for
Windows (SAS Institute Inc., Cary, NC, USA).
Hardy–Weinberg equilibrium and linkage disequilibrium were
evaluated by PyPop on line free software (University of California,
Berkley, USA) (Lancaster et al, 2003).
RESULTS
Clinical data
A total of 130 patients (46 women and 84 men) were the study
population. All had a Karnofsky performance status score between
100 and 80. Mean age was 63.7±10.3, ranging from 34 to 84 years.
The primary tumour site was right colon in 47 cases and left colon
in 83 cases. Duke’s tumour stage was B2 in 51 patients and C in 79
patients. Stage C was more frequently found in patients aged X65
years than in those aged o65 (80.3 vs 42.2%; Po0.0001).
A total of 116 patients were treated for all six planned cycles; 10
patients stopped the treatment prematurely because of toxicity,
mainly at the first or second cycle, and four patients stopped
because of disease progression. The true cumulative dose was, on
average, 74.1±20.2% (range: 14.4–101.6%) of the theoretical one,
and dose reduction was significantly greater in patients aged X65
(30.5±19.0%) than o65 (21.1±20.5%) (Po0.0075).
During chemotherapy, 45 (35%) patients suffered from grade 3–
4 toxicity, mainly mucositis (28%), diarrhea (10%) and neutrope-
nia (8%). During follow-up (median 3.8 years, range 0.4–8.5
years), 44 patients had documented recurrent disease and 31 died,
three for non cancer-related causes. Overall survival rates were
87.6% at 3 years and 73.5% at 5 years. The 3- and 5-year DFS rates
were 69.8 and 62.2%, respectively.
Pharmacokinetic data
The mean 5FU starting dose was 724.5±88.2mg (range:
350–920mg) and the related pharmacokinetic parameters were
broadly variable among patients (AUC range: 146–1236mgl
–1 min;
CL range: 0.0084–0.0705lmin
–1Kg
–1). 5FU clearance measured at
the first cycle was inversely correlated with the percent dose
reduction during the following cycles: the lower the CL, the greater
the reduction in the cumulative dose, with a linear trend across the
CL quartiles (ANOVA, Po0.0001; linear trend, Po0.0001)
(Figure 1).
Genetic data
The frequency of TYMS and MTHFR genotypes found in our
population was similar to that reported earlier in white popula-
tions, and allelic distributions were in Hardy–Weinberg equili-
brium. Strong-linkage disequilibrium was found for 50UTR VNTR
and 30UTR polymorphisms (d0 ¼0.81; Po0.0001), 50UTR G4C
and 30UTR polymorphisms (d0 ¼0.52; Po0.0001) and MTHFR
C677T and A1298C polymorphisms (d0 ¼0.96, Po0.0001). TYMS
and MTHFR genotype distributions were not significantly different
between stages B2 and C, males and females, patients aged o65
and X65 years.
Toxicity analysis
Univariate analysis showed that low-5FU CL had a highly
significant effect on severe toxicity (Po0.0001). Among the other
variables, only age was marginally significant (P¼0.059) (Table 3).
Multivariate analysis confirmed low-5FU CL (Po0.0001) as an
independent prognostic factor for grade 3–4 toxicity (OR¼7.32,
95% CI: 3.06–17.51, Po0.0001); in addition, the ‘high-activity’
MTHFR 677 CC genotype proved to be associated with a reduced
risk of side-effects (T/T vs C/C OR¼1.17, 95% CI: 0.34–4.08; C/T
vs C/C OR¼3.10, 95% CI: 1.21–7.94, P¼0.040). When specific
toxicity type was considered, severe mucositis was predicted only
by low 5FU CL (OR¼7.92, 95% CI: 3.00–20.91, Po0.0001),
whereas no variable predicted diarrhea and neutropenia.
Survival analysis
Survival analysis was restricted to the 122 patients who completed
at least three chemotherapy cycles, that is, those who received at
least 50% of the planned cumulative dose, in order to exclude the
patients whose clinical outcome could not be reasonably ascribed
to 5FU treatment. Univariate analysis showed that advanced age
and Dukes’ stage C had a significant negative prognostic effect on
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Figure 1 Mean cumulative 5FU dose administered, as percentage of
initially planned dose, in each 5FU clearance quartile. Bars represent
standard errors. Four patients who stopped therapy because of disease
progression were excluded from analysis.
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sDFS, and that high-5FU CL was significantly related with a worse
OS (Table 4). Conversely, sex, cumulative dose reduction and onset
of severe toxicity had no predictive value. Also, no significant
association was observed between DFS or OS and any TYMS
or MTHFR polymorphisms, either analysed separately or in
combination.
In the multivariate Cox-regression model, advanced age and
high-5FU clearance proved to be unfavourable prognostic factors
for both DFS and OS. An age X65 was associated with an HR of
3.34 for relapsing (95% CI: 1.65–6.75; P¼0.0008) and 2.66 for
dying (95% CI: 1.32–8.64; P¼0.024). Patients with CL
X0.017lmin
–1Kg
–1 had a cancer-related death risk 3.37 times
higher (95% CI: 1.32–8.64; P¼0.011) and a disease-recurrence
risk 1.96 times higher (95% CI: 1.03–3.73; P¼0.041) than patients
with CL o0.017lmin
–1Kg
–1.
When patients were stratified according to CL and age in four
groups (Figure 2), those with high CL and aged X65 survived less
(HR: 6.50; 95% CI: 1.44–29.36; P¼0.015) and relapsed earlier (HR:
5.99; 95% CI: 1.95–18.51; P¼0.0018) than those with low CL and
aged o65, who had the best outcome.
A significant difference in DFS was also observed between
old/high CL and young/high CL patients (log-rank test: P¼0.025)
and between old/low CL and young/low CL patients (P¼0.047).
In addition, OS of patients aged 465 and with high CL
was significantly worse than that of any other group (P range:
0.012–0.009). The comparisons between the other groups did not
reach the significance level.
Frequency of Duke’s C stage was lower in the younger/low CL
group than in the older/high CL group (42.3 vs 81.5%, P¼0.0033),
whereas severe toxicity was more frequent in the former group
than in the latter (42.3 vs 18.5%, P¼0.059). Nevertheless, as stated
above, in the overall population neither C Duke’s stage nor severe
toxicity were markers of OS/DFS, as their predictive value in the
multivariate analysis was probably included in age and CL,
respectively.
DISCUSSION
The main clinical implication emerging from our study is that
high-5FU CL (X0.017lmin
–1Kg
–1), measured at the beginning of
the adjuvant chemotherapy course in colorectal patients, is the
strongest single predictor of reduced toxicity and poor clinical
outcome in terms of both DFS and OS. Multivariate analysis also
showed that age X65 was associated with shorter DFS and OS but
not with more severe toxicity, suggesting that preventive dose
reduction in elderly patients is not advisable. As a whole, the
association of high-5FU CL with advanced age had the worse
prognostic meaning for both DFS and OS. Furthermore, patients
homozygous C/C for C677T MTHFR, who are presumed to have-
high enzyme activity, had a lower-toxicity risk.
With respect to 5FU tolerability, our findings are in good
agreement with earlier literature data, as high AUC or low CL have
invariably been associated with more severe 5FU toxicity after any
administration schedule (Young et al, 1999; Di Paolo et al, 2002;
Jansman et al, 2002; Ychou et al, 2003; Codacci-Pisanelli et al,
2005; Gusella et al, 2006b; Capitain et al, 2008). A recent, large,
prospective trial (Schwab et al, 2008) on cancer patients treated
with 5FU monotherapy confirmed a significant– –although
weak– –link between mutant MTHFR C677T genotypes and FU
toxicity but, at odds with our results, also found a significant
correlation with the 2R/2R TYMS genotype. A correlation between
5FU toxicity and the VNTR TYMS polymorphism has also been
reported by Lecomte et al (2004) and Pullarkat et al (2001), who
found less toxicity in patients with the 3R/3R genotype. Indeed,
our univariate analysis also suggests a non-significant trend
toward a decreased toxicity risk in patients carrying the 3R/3R
genotype in comparison with carriers of the 2R/2R TYMS genotype
(OR¼0.55). A significant correlation with C677T MTHFR
genotype, but not with TYMS genotypes, was also found by
Sharma et al (2008) in colorectal patients treated with capecita-
bine, a 5FU prodrug.
With respect to factors correlated with therapeutic outcomes,
age and 5FU CL turned out to be the only significant predictors of
DFS and OS in our study. The association between age and clinical
outcome may be partly explained by the greater prevalence of stage
C in our older patients. However, other studies found that
advanced age is an independent risk factor (Gill et al, 2004;
Schippinger et al, 2007). Similarly, an association between low 5FU
Table 3 Univariate logistic regression of toxicity in 130 patients
adjuvantly treated with 5FU chemotherapy
TOXICITY
n Events P OR 95% CI
Sex
Female 46 17 0.68 1 —
Male 84 28 0.85 0.40–1.81
Age (years)
o65 64 17 0.06 1 —
X65 66 28 2.04 0.97–4.26
TYMS VNTR
2R2R 25 10 0.38 1 —
2R3R 60 23 0.93 0.36–2.42
3R3R 45 12 0.55 0.19–1.54
TYMS G4C
Low activity 72 25 0.98 1 —
High activity 58 20 0.99 0.48–2.047
TYMS 30UTR
ins/ins 46 20 0.10 1 —
ins/del 68 23 0.66 0.31–1.43
del/del 16 2 0.19 0.04–0.91
TYMS comb A
Low activity 69 25 0.68 1 —
High activity 61 20 0.86 0.41–1.77
TYMS comb B
Low 34 11 0.09 1 —
Intermediate 88 28 0.98 0.42–2.28
High 8 6 6.27 1.09–36.22
MTHFR C677T
C/C 44 11 0.08 1 —
C/T 63 28 2.40 1.03C5.58
T/T 23 6 1.06 0.33–3.36
MTHFR A1298C
A/A 54 22 0.12 1 —
A/C 59 21 0.80 0.38–1.72
C/C 17 2 0.19 0.04–0.93
MTHFR combined
Low 42 16 0.75 1 —
Intermediate 78 25 0.77 0.35–1.68
High 10 4 1.08 0.26–4.44
5FU CL (lmin
 1Kg
 1)
X0.017 65 10 o0.0001 1 —
o0.017 65 35 6.42 2.79–14.74
Abbreviations: CI¼confidence interval; CL¼plasma clearance; MTHFR¼methylene-
tetrahydrofolate reductase; OR¼odds ratio; UTR¼untranslated region; VNTR¼vari-
able number tandem repeats.
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reported in cancer patients treated with either continuous 5FU
infusion (Milano et al, 1994; Gamelin et al, 1996) or Machover’s
bolus administration schedule (Di Paolo et al, 2008).
DPD governs 5FU catabolism in both normal and tumour cells,
and a significant correlation has been shown between DPD
expression in colorectal tumours and the surrounding intestinal
mucosa (Tanaka-Nozaki et al, 2001; Amatori et al, 2006). Thus, on
Table 4 Univariate Cox regression of disease free and overall survival in the 122 patients adjuvantly treated with 5FU chemotherapy for at least three
cycles
DFS OS
n Events P HR 95% CI Events P HR 95% CI
Sex
Female 41 13 0.86 1 — 7 0.60 1 —
Male 81 27 1.06 0.55–2.06 17 1.26 0.52–3.05
Age (years)
o65 60 13 0.003 1 — 9 0.08 1 —
X65 62 27 2.90 1.46–5.79 15 2.12 0.91–4.91
Dukes’ stage
B2 46 10 0.04 1 — 6 0.16 1 —
C 76 30 2.10 1.02–4.30 18 1.94 0.77–4.89
Toxicity grade
0–2 81 25 0.43 1 — 17 0.68 1 —
3–4 41 15 1.30 0.68–2.47 7 0.83 0.34–2.01
TYMS VNTR
2R2R 23 11 0.24 1 — 7 0.34 1 —
2R3R 57 18 0.63 0.30–1.35 12 0.72 0.28–1.83
3R3R 42 11 0.49 0.21–1.14 5 0.42 0.13–1.34
TYMS G4C
Low activity 68 23 0.79 1 — 15 0.58 1 —
High activity 54 17 0.92 0.49–1.72 9 0.79 0.35–1.81
TYMS 30UTR
ins/ins 44 13 0.65 1 — 8 0.67 1 —
ins/del 63 24 1.29 0.66–2.53 15 1.30 0.55–3.06
del/del 15 3 0.84 0.24–2.98 1 0.59 0.07–4.80
TYMS comb. A
Low 64 25 0.15 1 — 16 0.22 1 —
High 58 15 0.62 0.33–1.18 8 0.58 0.24–1.38
TYMS comb. B
Low activity 32 12 0.69 1 — 8 0.58 1 —
Intermediate 82 26 0.74 0.37–1.48 15 0.64 0.27–1.50
High activity 8 2 0.71 0.16–3.17 1 0.64 0.08–4.95
MTHFR C677T
C/C 41 13 0.54 1 — 8 0.86 1 —
C/T 59 18 0.85 0.42–1.74 11 0.83 0.33–2.06
T/T 22 9 1.34 0.57–3.14 5 1.07 0.35–3.27
MTHFR A1298C
A/A 49 17 0.73 1 — 9 0.86 1 —
A/C 57 19 0.82 0.42–1.60 13 1.01 0.43–2.38
C/C 16 4 0.68 0.23–2.02 2 0.67 0.14–3.10
MTHFR comb.
Low 41 12 0.30 1 — 9 0.95 1 —
Intermediate 72 26 1.62 0.81–3.24 13 1.10 0.46–2.59
High 9 2 0.83 0.18–3.72 2 1.28 0.27–5.98
CL (lmin
–1Kg
–1)
o0.017 61 16 0.17 1 — 6 0.032 1 —
X0.017 61 24 1.56 0.83–2.95 18 2.76 1.09–6.99
% Dose reduction Continuous 0.16 1.02 0.99–1.04 0.27 1.02 0.99–1.04
Abbreviations: CI¼confidence interval; CL¼plasma clearance; DFS¼disease-free survival; HR¼hazard ratio; MTHFR¼methylenetetrahydrofolate reductase; OS¼overall
survival; UTR¼untranslated region; VNTR¼variable number tandem repeats.
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tumour and, on the other, decrease 5FU inactivation inside it. In
line with this view, several studies in colorectal cancer patients
treated with 5FU-based adjuvant therapy have shown that low-
DPD protein or mRNA expression in the tumour is associated with
longer DFS and OS (Popat et al, 2004; Ciaparrone et al, 2006;
Jensen et al, 2006; Lassmann et al, 2006; Popat et al, 2006; Yamada
et al, 2008), whereas no consistent correlation has been shown with
TS tumour expression (Kamoshida et al, 2004; Aguiar et al, 2005;
Ciaparrone et al, 2006; Jensen et al, 2006; Lassmann et al, 2006;
Popat et al, 2006; Soong et al, 2008; Yamada et al, 2008). Indeed, in
our study, none of the three TS polymorphisms, considered alone
or in combination (VNTR, G4C substitution, 6bp insertion-
deletion), could predict the clinical outcome. This negative results
may be because of an insufficient power of our study to detect
genetic associations or to some inaccuracy in grouping the
genotypes. However, our population size was comparable with
that of other similar studies and genotype classifications reflected
the best available information on gene biological activity. In this
respect, literature data are inconclusive in that the same TS
polymorphisms have been correlated with both favourable and
unfavourable effects, and no correlation has even been reported
(Dotor et al, 2006; Gusella and Padrini, 2007; Gosens et al, 2008;
Fernandez-Contreras et al, 2009). Besides the methodological
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Figure 2 Disease-free (A) and overall survival (OS) plots (B) of patients stratified in four groups according to age (o or X65 years) and 5FU clearance
(o or X0.017mgl
 1Kg
 1). Open circles indicate censored data points. Log-rank test was significant for both disease-free survival (DFS) (P¼0.0012) and
overall survival (OS) (P¼0.0036).
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sdifferences between clinical trials, a number of biological factors
may have obscured the link between TYMS polymorphisms and
5FU activity. First, it is known that 5FU can not only inhibit TS but
also affect mRNA function. Sobrero et al (1997) have suggested,
and others (Kubota et al, 2002; Matsusaka et al, 2003; Hoshino
et al, 2005) have experimentally confirmed, that 5FU incorporation
into colorectal tumour mRNA is significantly greater after bolus
than after continuous infusion. If this is true, RNA-mediated
effects may prevail over TS inhibition, and TS expression may play
only an ancillary role in the antitumour activity of 5FU bolus
administration. Second, translation of TS mRNA is inhibited by TS
protein in an autoregulatory manner (Chu et al, 1991), so that the
influence of gene polymorphisms may be blunted. Third, it has
been reported that 5FU treatment can induce a variable,
compensatory increase in TS mRNA levels in colorectal tumours
(Ukida et al, 2001; Tanaka-Nozaki et al, 2003) and that patients
with no or minor mRNA increase show a better response to
therapy (Ukida et al, 2001). Fourth, the 50-UTR polymorphism is in
linkage disequilibrium with the 30-UTR polymorphism, in that the
þ6/þ6bp and  6/ 6bp genotypes are associated with 2R/2R
and 3R/3R genotypes, respectively (Mandola et al, 2004). It is
therefore likely that the coexistence in the same gene of high- and
low-expression genotypes may attenuate functional consequences.
Fifth, TS tumour levels may be simultaneously markers of tumour
aggressiveness and tumour sensitivity to 5FU. In this regard, a
recent, large study (Soong et al, 2008) reported that low-TS
expression was correlated with worse prognosis in colorectal
patients treated with surgery alone whereas no significant effect on
survival was noted in the 5FU-treated group. As it is generally
acknowledged that low TS-expressing tumours are more sensitive
to 5FU (Gusella and Padrini, 2007), the lack of prognostic
significance of low TS levels in 5FU-treated patients may be
explained by a concomitant harmful effect on tumour growth.
The prognostic role of the MTHFR polymorphism in the
response to 5FU did not emerge from our study. No studies with
adjuvant therapy are available for a comparison, although contra-
dictory results come from studies in other clinical settings (Cohen
et al, 2003; Etienne et al, 2004; Jakobsen et al, 2005; Terrazzino
et al, 2006; Ruzzo et al, 2007; Zhang et al, 2007). The reasons for
such discrepancies are unclear.
In conclusion, our study makes a contribution to the
controversial issue of which colorectal patients are more likely to
gain benefit from 5FU adjuvant chemotherapy. One strength of our
investigation is the simultaneous evaluation of an index of
drug exposure (5FU CL) and of several TYMS and MTHFR
polymorphisms possibly related to tumour sensitivity, in a group
of patients homogeneously treated with a repeated bolus regimen.
The finding that patients’ demographic and pharmacokinetic
characteristics are more predictive of clinical outcome than some
putative genetic markers suggests that the traditional, phenotypic
approach to clinical cancer research should not be abandoned and
that the genetic approach requires further work to prove its clinical
usefulness. Feasibility and utility of a pharmacokinetic test to
assess 5FU CL in colorectal patients starting adjuvant therapy need
to be evaluated in a prospective trial.
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